Recognizing the Value of Radiation Therapy in Lung Cancer
Randy Stevens, MD, discusses the growing role for radiation in lung cancer, delivery techniques, and adverse effect management strategies.
Surgery Stakes Claim in Lung Cancer Despite Evolution of Systemic Therapy
Surgical resection should be a standard of care for patients with stage I to IIIA lung cancer, but probing for subclinical stage III disease with endobronchial ultrasound guided biopsy or mediastinoscopy to determine whether surgery should be performed prior to or after systemic therapy.
Dr. Costin on Initial Considerations in Early-Stage Lung Cancer
Dan Costin, MD, discusses initial considerations in early-stage lung cancer.
Dr. Sabari on the Role of Concurrent Molecular Testing in Lung Cancer
Joshua K. Sabari, MD, discusses the role of concurrent plasma- and tissue-based molecular testing in lung cancer.
Sabari Stresses the Importance of Molecular Testing in Lung Cancer
Joshua K. Sabari, MD, discussed the management of patients with early-stage and metastatic lung cancer, the roles of molecular testing, surgery, staging, and ongoing research efforts in the space.
Dr. Stiles on Treatment Advances Made in Early-Stage Lung Cancer
Brendon Stiles, MD, discusses the roles of surgery, radiation, and chemotherapy in treatment for early-stage lung cancer.
Dr. Rohs on the Role of Molecular Testing in Lung Cancer Management
Nicholas C. Rohs, MD, discusses the role of molecular testing in patients with lung cancer.
Navigating Nuances in Early and Metastatic Lung Cancer Treatment
Brendon Stiles, MD, discusses his approach to treating patients with early-stage and metastatic lung cancer, the importance of molecular testing and screening, and remaining challenges in the space.
Capitalizing on Multimodality Therapy in NSCLC
Balazs Halmos, MD, discussed differences in the management of early- vs late-stage non–small cell lung cancer and the erasure of single-modality therapy across the field.
Rohs Reflects on Therapeutic Approaches in Early- Vs Late-Stage Lung Cancer
Nicholas C. Rohs, MD, highlights the influx of clinical trials and the addition of immunotherapy in the adjuvant setting of lung cancer.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512